From The BBC:
Drugs giant GlaxoSmithKline says it expects to triple capacity of its flu treatment Relenza to 190 million treatments per year.Glaxo also said it had received contracts for 195 million doses of the H1N1 vaccine for swine flu, adding that it was on track to meet the orders. It said it was involved in continuing talks with more than 50 governments to supply pandemic products. Glaxo said pre-tax profits in the three months to 30 June fell 6% to £2.1bn. Group turnover during the quarter was down 2% to £6.7bn. Increasing productionGlaxo said its performance had been boosted by sales of Relenza, “reflecting continued orders from governments across the world for pandemic stock-piling”. Sales of the treatment were £60m in the quarter, compared with £3m in the same period a year ago. Since the outbreak of swine flu, Glaxo said it had committed to increasing production levels of Relenza and effectively developing a new H1N1 vaccine. Shipments of the vaccine are expected i…
Leave a Reply